Cited by 358Obsessive-Compulsive Spectrum DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychoanalysis and Psychopathology Research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Augmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive Disorder

Wilhelm, Sabine, Buhlmann, Ulrike, Tolin, David F., Meunier, Suzanne A., Pearlson, Godfrey D., Reese, Hannah E., Cannistraro, Paul, Jenike, Michael A., Rauch, Scott L.·2008·American Journal of Psychiatry

DOI 10.1176/appi.ajp.2007.07050776

Open this paper in CoChat — free account

Abstract

OBJECTIVE: This study examined whether d-cycloserine, a partial agonist at the N-methyl-D-aspartate (NMDA) glutamatergic receptor, enhances the efficacy of behavior therapy for obsessive-compulsive disorder (OCD). METHOD: A randomized, double-blind, placebo-controlled trial investigating D-cycloserine versus placebo augmentation of behavior therapy was conducted in 23 OCD patients. Patients first underwent a diagnostic interview and pretreatment evaluation, followed by a psychoeducational/treatment planning session. Then they received 10 behavior therapy sessions. Treatment sessions were conducted twice per week. One hour before each of the behavior therapy sessions, the participants received either D-cycloserine, 100 mg, or a placebo. RESULTS: Relative to the placebo group, the D-cycloserine group's OCD symptoms were significantly more improved at mid-treatment, and the D-cycloserine group's depressive symptoms were significantly more improved at posttreatment. CONCLUSIONS: These data provide support for the use of D-cycloserine as an augmentation of behavior therapy for OCD and extend findings in animals and other human disorders suggesting that behavior therapy acts by way of long-term potentiation of glutamatergic pathways and that the effects of behavior therapy are potentiated by an NMDA agonist.

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2007.07050776

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Structured Clinical Interview for DSM-IV Axis I Disorders
Spitzer, R. L., First, M. B., & Gibbon, M. (1997) · Medical Entomology and Zoology · Cited by 3,582
Fear conditioning induces associative long-term potentiation in the amygdala
Rogan, M. T., Stäubli, U. V., & LeDoux, J. E. (1997) · Nature · doi:10.1038/37601 · Cited by 1,310
Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinctionof Fear
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive–compulsive disorder
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
Why We Think Plasticity Underlying Pavlovian Fear Conditioning Occurs in the Basolateral Amygdala
Fanselow, M. S., & LeDoux, J. E. (1999) · Neuron · doi:10.1016/s0896-6273(00)80775-8 · Cited by 933
Facilitation of Conditioned Fear Extinction by Systemic Administration or Intra-Amygdala Infusions of d-Cycloserine as Assessed with Fear-Potentiated Startle in Rats
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560 · cited 4×
“on social anxiety (14), in our OCD study, the medication was given 1 hour before each session.”
BackgroundMethodInfluential
Treatment of obsessive–compulsive disorder: Cognitive behavior therapy vs. exposure and response prevention
Whittal, M. L., Thordarson, D. S., & McLean, P. D. (2005) · Behaviour Research and Therapy · doi:10.1016/j.brat.2004.11.012 · Cited by 417

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 4

Cox J, 1994, Q J Exp Psychol B, 47, 187
Kozak MJ, 1997, Tex
First MB, 1995, Patient Edition (SCIDP, version 2.0).
Beck AT, 1996, Steer RA

Sorted by citations

Items 101–200 of 358

Enhancement of psychosocial treatment with D-cycloserine: Models, moderators, and future directions
Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A., van Minnen, A., Evins, A. E., & Pollack, M. H. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.09.007 · Cited by 70
Self-citation
Cognitive Behavior Therapy for Obsessive-Compulsive and Related Disorders
Lewin, A. B., Wu, M. S., Mcguire, J. F., & Storch, E. A. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.05.002 · Cited by 73
Effectiveness of Medication Combined with Intensive Behavioral Intervention for Reducing Aggression in Youth with Autism Spectrum Disorder
Frazier, T. W., Youngstrom, E. A., Haycook, T., Sinoff, A., Dimitriou, F., Knapp, J. A., & Sinclair, L. V. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0048 · Cited by 69
d-Cycloserine Augmentation of Behavioral Therapy for the Treatment of Anxiety Disorders: A Meta-Analysis
Bontempo, A., Panza, K. E., & Bloch, M. H. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r07356 · Cited by 69
The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders
Peyrovian, B., Rosenblat, J. D., Pan, Z., Iacobucci, M., Brietzke, E. M., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.02.001 · Cited by 76
Cognitive enhancers for anxiety disorders
Hofmann, S. G., Smits, J. A. J., Asnaani, A., Gutner, C. A., & Otto, M. W. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.11.020 · Cited by 69
Does Yohimbine Hydrochloride Facilitate Fear Extinction in Virtual Reality Treatment of Fear of Flying? A Randomized Placebo-Controlled Trial
Meyerbröker, K., Powers, M. B., van Stegeren, A. H., & Emmelkamp, P. M. G. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000329454 · Cited by 69
Cognitive function as an emerging treatment target for marijuana addiction.
Sofuoglu, M., Sugarman, D. E., & Carroll, K. M. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0019295 · Cited by 66
Augmentation of Cognitive Behavioral Therapy with Pharmacotherapy
Ganasen, K. A., Ipser, J., & Stein, D. J. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.04.008 · Cited by 68
Treatment of Pediatric Obsessive-Compulsive Disorder: A Review
Mancuso, E., Faro, A. L., Joshi, G., & GELLER, D. A. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0040 · Cited by 67
A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder
Stein, D. J., Koen, N., Fineberg, N., Fontenelle, L. F., Matsunaga, H., Osser, D., & Simpson, H. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0268-9 · Cited by 65
Current trends in drug treatment of obsessive–compulsive disorder
Decloedt, E. H., & Stein, D. J. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3149 · Cited by 65
Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder
Askari, N., Moin, M., Sanati, M. H., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Najand, B., Salimi, S., Tabrizi, M. H., Ashrafi, M., et al. (2012) · CNS Drugs · doi:10.2165/11635850-000000000-00000 · Cited by 65
Intensive residential treatment for severe obsessive-compulsive disorder: Characterizing treatment course and predictors of response
Brennan, B. P., Lee, C., Elias, J. A., Crosby, J. M., Mathes, B. M., André, M., Gironda, C. M., Pope, H. G., Jenike, M. A., Fitzmaurice, G. M., et al. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.05.008 · Cited by 64
Self-citation
Cognitive–behavioural therapy with post-session d-cycloserine augmentation for paediatric obsessive–compulsive disorder: pilot randomised controlled trial
Mataix‐Cols, D., Turner, C. M., Monzani, B. A., Isomura, K., Murphy, C., Krebs, G., & Heyman, I. (2013) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.126284 · Cited by 64
Frequency of reporting of adverse events in randomized controlled trials of psychotherapy vs. psychopharmacotherapy
Vaughan, B., Goldstein, M. H., Alikakos, M., Cohen, L. J., & Serby, M. J. (2014) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2014.01.001 · Cited by 63
Glutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62
d-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders
Hofmann, S. G., Wu, J. Q., & Boettcher, H. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-11 · Cited by 59
Pharmacological Treatment of Obsessive-Compulsive Disorder
Simpson, H. B. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_12 · Cited by 59
Cognitive enhancers for facilitating drug cue extinction: Insights from animal models
Dhonnchadha, B. Á. N., & Kantak, K. M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.018 · Cited by 57
Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder
McGuire, J. F., Lewin, A. B., & Storch, E. A. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.934677 · Cited by 57
“[46] identified improvement among participants receiving DCS relative to placebo at the mid-treatment assessment, with post hoc analyses identifying that therapeutic gains were achieved more quickly for participants receiving DCS relative to placebo [54].”
Background
Pharmacological enhancement of fear reduction: preclinical models
Graham, B. M., Langton, J. M., & Richardson, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01175.x · Cited by 57
Effect of d-cycloserine and valproic acid on the extinction of reinstated fear-conditioned responses and habituation of fear conditioning in healthy humans: a randomized controlled trial
Kuriyama, K., Honma, M., Soshi, T., Fujii, T., & Kim, Y. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2353-x · Cited by 54
Mechanisms of Action in Exposure Therapy
Knowles, K. A., & Tolin, D. F. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01391-8 · Cited by 54
Self-citation
Obsessive-compulsive disorder: Evidence-based treatments and future directions for research
Lack, C. W. (2012) · World Journal of Psychiatry · doi:10.5498/wjp.v2.i6.86 · Cited by 52
NMDA receptor activation regulates sociability by its effect on mTOR signaling activity
Burket, J. A., Benson, A. D., Tang, A., & Deutsch, S. I. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.02.009 · Cited by 53
A Meta-Analysis of d-Cycloserine in Exposure-Based Treatment
Mcguire, J. F., Wu, M. S., Piacentini, J. C., McCracken, J. T., & Storch, E. A. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15r10334 · Cited by 52
d-Cycloserine enhances durability of social skills training in autism spectrum disorder
Wink, L. K., Minshawi, N. F., Shaffer, R. C., Plawecki, M. H., Posey, D. J., Horn, P. S., Adams, R. E., Pedapati, E. V., Schaefer, T. L., McDougle, C. J., et al. (2017) · Molecular Autism · doi:10.1186/s13229-017-0116-1 · Cited by 51
Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive–compulsive disorder
Heidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000043 · Cited by 48
Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach
Grados, M. A., Specht, M. W., Sung, H.-M., & Fortune, D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.845553 · Cited by 49
Vagus nerve stimulation as a tool for enhancing extinction in exposure-based therapies
Noble, L. J., de Souza, R. R., & McIntyre, C. K. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4994-5 · Cited by 48
Latinos with obsessive-compulsive disorder: Mental healthcare utilization and inclusion in clinical trials
Wetterneck, C. T., Little, T. E., Rinehart, K. L., Cervantes, M. E., Hyde, E., & Williams, M. T. (2012) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2011.12.001 · Cited by 51
D-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disorders
Modi, M. E., & Young, L. J. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.026 · Cited by 47
Pharmacological Enhancement of Behavioral Therapy: Focus on Posttraumatic Stress Disorder
Choi, D. C., ROTHBAUM, B. O., Gerardi, M. A., & Ressler, K. J. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_10 · Cited by 47
Does d-Cycloserine Augmentation of CBT Improve Therapeutic Homework Compliance for Pediatric Obsessive–Compulsive Disorder?
Park, J. M., Small, B. J., GELLER, D. A., Murphy, T. K., Lewin, A. B., & Storch, E. A. (2013) · Journal of Child and Family Studies · doi:10.1007/s10826-013-9742-1 · Cited by 49
Stress modulation of cognitive and affective processes
Campeau, S., Liberzon, I., Morilak, D. A., & Ressler, K. J. (2011) · Stress · doi:10.3109/10253890.2011.596864 · Cited by 50
Progress in Cue Exposure Therapy for the Treatment of Addictive Disorders: A Review Update
Martin, T., LaRowe, S. D., & Malcolm, R. J. (2013) · The Open Addiction Journal · doi:10.2174/1874941001003010092 · Cited by 46
Advances in pharmacotherapy for pediatric anxiety disorders
Rynn, M. A., Puliafico, A. C., Heleniak, C. M., Rikhi, P., Ghalib, K., & Vidair, H. B. (2011) · Depression and Anxiety · doi:10.1002/da.20769 · Cited by 45
Obsessive Compulsive Disorder: A Comparison of CBT and the Metacognitive Approach
Fisher, P. (2009) · International Journal of Cognitive Therapy · doi:10.1521/ijct.2009.2.2.107 · Cited by 44
Anxiety disorders
Klein, R. G. (2009) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2008.02061.x · Cited by 49
The role of NMDA receptors in the signal attenuation rat model of obsessive–compulsive disorder
Albelda, N. S., Bar-On, N., & Joel, D. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1808-9 · Cited by 43
D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: a meta-analysis
Bürkner, P.-C., Bittner, N., Holling, H., & Buhlmann, U. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173660 · Cited by 41
Self-citation
Galantamine improves sustained attention in chronic cocaine users.
Sofuoglu, M., Waters, A. J., Poling, J. C., & Carroll, K. M. (2011) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0022213 · Cited by 41
Efficacy of Glutamate Modulators in Tic Suppression: A Double-Blind, Randomized Control Trial of D-serine and Riluzole in Tourette Syndrome
Lemmon, M. E., Grados, M. A., Kline, T., Thompson, C. B., Ali, S. F., & Singer, H. S. (2015) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2015.02.002 · Cited by 41
Sarcosine Therapy for Obsessive Compulsive Disorder
Wu, P.-L., Tang, H., Lane, H., Tsai, C., & Tsai, G. E. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182189878 · Cited by 40
The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap
Szechtman, H., Harvey, B. H., Woody, E. Z., & Hoffman, K. L. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017772 · Cited by 41
A selective review of glutamate pharmacological therapy in obsessive–compulsive and related disorders
Grados, M. A., Atkins, E., Kovacikova, G. I., & McVicar, E. L. (2015) · Psychology Research and Behavior Management · doi:10.2147/prbm.s58601 · Cited by 41
A Trial of D-Cycloserine to Treat the Social Deficit in Older Adolescents and Young Adults With Autism Spectrum Disorders
Urbano, M. R., Okwara, L., Manser, P., Hartmann, K., & Deutsch, S. I. (2015) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.13070155 · Cited by 43
Effect of D-Cycloserine on the Effect of Concentrated Exposure and Response Prevention in Difficult-to-Treat Obsessive-Compulsive Disorder
Kvale, G., Hansen, B. K. A., Hagen, K., Abramowitz, J. S., Børtveit, T., Craske, M. G., Franklin, M. E., Haseth, S., Himle, J. A., Hystad, S. W., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13249 · Cited by 38
Obsessive–compulsive Disorder: Diagnostic and Treatment Issues
Stein, D. J., Denys, D. A. J. P., Gloster, A. T., Hollander, E., Leckman, J. F., Rauch, S. L., & Phillips, K. A. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.007 · Cited by 37
Self-citation
MRSI correlates of cognitive–behavioral therapy in pediatric obsessive–compulsive disorder
O’Neill, J., Piacentini, J. C., Chang, S. W., Levitt, J. G., Rozenman, M. S., Bergman, L., Salamon, N., Alger, J. R., & McCracken, J. T. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.09.007 · Cited by 36
Successful pharmacotherapy for the treatment of severe feeding aversion with mechanistic insights from cross-species neuronal remodeling
Sharp, W. G., Allen, A. G., Stubbs, K. H., Criado, K. K., Sanders, R., McCracken, C. E., Parsons, R. G., Scahill, L. D., & Gourley, S. L. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.126 · Cited by 39
Effects of D-Cycloserine Administration on Weekly Nonemotional Memory Tasks in Healthy Participants
Otto, M. W., Basden, S. L., McHugh, R. K., Kantak, K. M., Deckersbach, T., Cather, C., GOFF, D. C., Hofmann, S. G., Berry, A. C., & Smits, J. A. J. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000172620 · Cited by 37
Valproic acid but not d-cycloserine facilitates sleep-dependent offline learning of extinction and habituation of conditioned fear in humans
Kuriyama, K., Honma, M., Yoshiike, T., & Kim, Y. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.045 · Cited by 36
An initial investigation into the processes of change in ACT, CT, and ERP for OCD.
Twohig, M. P., Whittal, M. L., Cox, J. M., & Gunter, R. W. (2010) · International Journal of Behavioral Consultation and Therapy · doi:10.1037/h0100898 · Cited by 36
Pharmacological enhancement of drug cue extinction learning: translational challenges
Kantak, K. M., & Dhonnchadha, B. Á. N. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05899.x · Cited by 35
D‐cycloserine‐augmented one‐session treatment of specific phobias in children and adolescents
Farrell, L. J., Waters, A. M., Oar, E. L., Tiralongo, E., Garbharran, V., Alston‐Knox, C., McConnell, H. W., Collings, N., Zimmer‐Gembeck, M. J., Donovan, C. L., et al. (2018) · Brain and Behavior · doi:10.1002/brb3.984 · Cited by 33
A pilot study of the effectiveness of d-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects
Watson, B. J., Wilson, S., Griffin, L., Kalk, N. J., Taylor, L. G., Munafo, M. R., Lingford-Hughes, A. R., & Nutt, D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2199-2 · Cited by 33
Obsessive-Compulsive and Related Disorders
Leigh, H. (2014) · Springer eBooks · doi:10.1007/978-3-319-11005-9_24 · Cited by 32
EFFECTS OF HOMEWORK COMPLIANCE ON COGNITIVE-BEHAVIORAL THERAPY WITH D-CYCLOSERINE AUGMENTATION FOR CHILDREN WITH OBSESSIVE COMPULSIVE DISORDER
Olatunji, B. O., Rosenfield, D., Monzani, B. A., Krebs, G., Heyman, I., Turner, C. M., Isomura, K., & Mataix‐Cols, D. (2015) · Depression and Anxiety · doi:10.1002/da.22423 · Cited by 35
Relevance of orbitofrontal neurochemistry for the outcome of cognitive-behavioural therapy in patients with obsessive–compulsive disorder
Zurowski, B., Kordon, A., Weber‐Fahr, W., Voderholzer, U., Kuelz, A. K., Freyer, T., Wahl, K., Büchel, C., & Hohagen, F. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0304-0 · Cited by 30
d-cycloserine facilitates procedural learning but not declarative learning in healthy humans: A randomized controlled trial of the effect of d-cycloserine and valproic acid on overnight properties in the performance of non-emotional memory tasks
Kuriyama, K., Honma, M., Koyama, S., & Kim, Y. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.02.017 · Cited by 31
Psychotherapy for obsessive-compulsive disorder
Storch, E. A., Mariaskin, A., & Murphy, T. K. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0043-8 · Cited by 30
Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications
Vlček, P., Polák, J., Brunovský, M., & Horáček, J. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-118665 · Cited by 32
Effects of d -Cycloserine on Craving to Alcohol Cues in Problem Drinkers: Preliminary Findings
Hofmann, S. G., Hüweler, R., MacKillop, J., & Kantak, K. M. (2011) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2011.600396 · Cited by 29
d-Cycloserine facilitates extinction learning and enhances extinction-related brain activation
Klass, A., Glaubitz, B., Tegenthoff, M., & Lissek, S. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.08.003 · Cited by 30
Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: A randomized placebo-controlled clinical trial
Sayyah, M., Olapour, A., Saeedabad, Y. S., Yazdan Parast, R., & Malayeri, A. (2012) · Nutrition · doi:10.1016/j.nut.2011.11.027 · Cited by 28
Neurobiology of maternal mental illness
Maguire, J., McCormack, C., Mitchell, A., & Monk, C. E. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64239-4.00005-9 · Cited by 28
Management of Treatment-Resistant Obsessive-Compulsive Disorder
Gershkovich, M., Wheaton, M. G., & Simpson, H. B. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0127-8 · Cited by 29
Innovations in the delivery of exposure and response prevention for obsessive-compulsive disorder
Patel, S. R., Comer, J., & Simpson, H. B. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2020_202 · Cited by 24
Cognitive enhancers for the treatment of anxiety disorders
Hofmann, S. G., Fang, A., & Gutner, C. A. (2014) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-139002 · Cited by 29
Combining d -cycloserine with motor training does not result in improved general motor learning in neurologically intact people or in people with stroke
Cherry‐Allen, K. M., Lenze, E. J., & Lang, C. E. (2014) · Journal of Neurophysiology · doi:10.1152/jn.00882.2013 · Cited by 28
Using cognitive enhancers to improve the treatment of anxiety disorders in young people: Examining the potential for D‐cycloserine to augment exposure for child anxiety
Byrne, S., Farrell, L. J., & Rapee, R. M. (2011) · Clinical Psychologist · doi:10.1111/j.1742-9552.2011.00005.x · Cited by 25
How to grade categories of evidence
Bandelow, B., Zohar, J., Kasper, S. F., & Möller, H. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802456590 · Cited by 26
Can Cognitive Behavioral Therapy for Anxiety and Depression Be Improved with Pharmacotherapy? A Meta-analysis
Tolin, D. F. (2017) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2017.08.007 · Cited by 25
Self-citation
D-cycloserine in the treatment of posttraumatic stress disorder
Baker, J., Cates, M. E., & Luthin, D. R. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.03.088 · Cited by 25
CBT-Plus: A meta-analysis of cognitive behavioral therapy augmentation strategies for obsessive-compulsive disorder
Guzick, A. G., Cooke, D. L., Gage, N. A., & McNamara, J. P. H. (2018) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2018.07.001 · Cited by 25
Clinical Pharmacology of Comorbid Obsessive–Compulsive Disorder in Tourette Syndrome
Neri, V., & Cardona, F. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00013-5 · Cited by 25
Pregabalin augmentation for resistant obsessive–compulsive disorder: a double-blind placebo-controlled clinical trial
Mowla, A., & Ghaedsharaf, M. (2019) · CNS Spectrums · doi:10.1017/s1092852919001500 · Cited by 27
An fMRI Study Examining Effects of Acute D-Cycloserine During Symptom Provocation in Spider Phobia
Aupperle, R. L., Hale, L. R., Chambers, R. J., Cain, S., Barth, F. X., Sharp, S., Denney, D. R., & Savage, C. R. (2009) · CNS Spectrums · doi:10.1017/s1092852900024044 · Cited by 24
d -Cycloserine Addition to Exposure Sessions in the Treatment of Patients With Obsessive-Compulsive Disorder
de Leeuw, A. S., van Megen, H. J. G. M., Kahn, R. S., & Westenberg, H. G. M. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2016.06.011 · Cited by 24
Glutamatergic augmentation strategies in obsessive–compulsive disorder
Narayanaswamy, J., & Sheshachala, K. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_520_18 · Cited by 24
New Pharmacotherapeutic Approaches to Obsessive-Compulsive Disorder
Figee, M., & Denys, D. A. J. P. (2009) · CNS Spectrums · doi:10.1017/s1092852900027255 · Cited by 24
Efficacy of D‐cycloserine augmented brief intensive cognitive‐behavioural therapy for paediatric obsessive‐compulsive disorder: A randomised clinical trial
Farrell, L. J., Waters, A. M., Tiralongo, E., Mathieu, S., McKenzie, M., Garbharran, V., Ware, R. S., Zimmer‐Gembeck, M. J., McConnell, H., Lavell, C., et al. (2022) · Depression and Anxiety · doi:10.1002/da.23242 · Cited by 23
Shared social competence impairment: Another link between the obsessive-compulsive and autism spectrums?
Chasson, G. S., Timpano, K. R., Greenberg, J. L., Shaw, A. M., Singer, T., & Wilhelm, S. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2011.02.006 · Cited by 24
Self-citation
A controlled trial of the adjunct use of d-cycloserine to facilitate cognitive behavioral therapy outcomes in a cocaine-dependent population
Kennedy, A., Gross, R. E., Whitfield, N., Drexler, K. P. G., & Kilts, C. D. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.03.008 · Cited by 20
Genome-wide association study of NMDA receptor coagonists in human cerebrospinal fluid and plasma
Luykx, J. J., Bakker, S. C., Visser, W. F., Verhoeven‐Duif, N. M., Buizer‐Voskamp, J. E., den Heijer, J. M., Boks, M. P., Sul, J. H., Eskin, E., Ori, A. P. S., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.190 · Cited by 21
N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series
Ameringen, M. V., Patterson, B. A., Simpson, W. S., & Turna, J. (2012) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2012.10.003 · Cited by 24
Obsessive-Compulsive Disorder: Diagnosis, Epidemiology, Etiology, and Treatment
Sassano-Higgins, S. A., & Pato, M. T. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130211 · Cited by 19
Glutamate-based anxiolytic ligands in clinical trials
Wierońska, J. M., & Pilc, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.803066 · Cited by 20
Assessment and Medication Management of Paediatric Obsessive-Compulsive Disorder
Stewart, S. E., Hezel, D. M., & Stachon, A. C. (2012) · Drugs · doi:10.2165/11632860-000000000-00000 · Cited by 20
No Effects of D-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia
Hofmeijer-Sevink, M. K., Duits, P., Rijkeboer, M. M., Hoogendoorn, A. W., van Megen, H. J. G. M., Vulink, N. C. C., Denys, D. A. J. P., van den Hout, M., van Balkom, A. J. L. M., & Cath, D. C. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000757 · Cited by 22
d-Cycloserine for the augmentation of an attentional training intervention for trait anxiety
Behar, E., McHugh, R. K., Peckham, A., & Otto, M. W. (2010) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2010.02.009 · Cited by 19
The Glutamate and the Immune Systems: New Targets for the Pharmacological Treatment of OCD
Marazziti, D., Albert, U., Mucci, F., & Piccinni, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666171108152035 · Cited by 19
Pavlovian Fear Conditioning
Fanselow, M. S., & Sterlace, S. R. (2014) · Wiley eBooks · doi:10.1002/9781118468135.ch6 · Cited by 26
Systemic administration of riluzole enhances recognition memory and facilitates extinction of fear memory in rats
Sugiyama, A., Saitoh, A., Inagaki, M., Oka, J., & Yamada, M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.06.007 · Cited by 18
D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis
Yu, X., Xia, J., Du, Y., Han, J., & Liu, G. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s68994 · Cited by 18
Cycloserine induced mania
Bakhla, A. K., Gore, P., & Srivastava, S. (2013) · Industrial Psychiatry Journal · doi:10.4103/0972-6748.123636 · Cited by 16
Recent advances in the treatment of anxiety disorders.
Antony, M. M. (2011) · Canadian Psychology/Psychologie canadienne · doi:10.1037/a0022237 · Cited by 20
Advances in the treatment of pediatric obsessive–compulsive disorder: rationale and design for the evaluation of D -cycloserine with exposure and response prevention
Mcguire, J. F., Lewin, A. B., GELLER, D. A., Brown, A., Ramsey, K. A., Mutch, J., Andrew Mittelman, B., Micco, J. A., Jordan, C., Wilhelm, S., et al. (2012) · Neuropsychiatry · doi:10.2217/npy.12.38 · Cited by 17
Self-citation

Authors: Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L.
Affiliations: Harvard University (US)
ORCID: Wilhelm, Sabine
Buhlmann, Ulrike
Tolin, David F.
Pearlson, Godfrey D.
Reese, Hannah E.
Jenike, Michael A.
Rauch, Scott L.
Venue: American Journal of Psychiatry
Publisher: American Psychiatric Association Publishing
Published: 2008-03
Volume: 165
Issue: 3
Pages: 335-341
ISSN: 0002-953X (ISSN-L)
1535-7228
DOI: 10.1176/appi.ajp.2007.07050776
OpenAlex: W2038335379
Semantic Scholar: d1309dc52689e30eae911778d6e9c8b6cc61a87f
Cited by: 358
References: 30
Citations by year: 2026: 2 · 2025: 1 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 11 · 2018: 16 · 2017: 24 · 2016: 13 · 2015: 24 · 2014: 36 · 2013: 33 · 2012: 41
FWCI: 48.90
Type: journal article
Language: en
Open access: closed
Locations: American Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords: D-cycloserine, obsessive-compulsive disorder, behavior therapy, augmentation therapy, NMDA receptor partial agonist, glutamatergic pathways, long-term potentiation, depressive symptoms
MeSH terms: Adult, Animals, Behavior Therapy, Combined Modality Therapy, Cycloserine, Double-Blind Method, Female, Follow-Up Studies, Humans, Implosive Therapy, Obsessive-Compulsive Disorder, Placebos, Psychiatric Status Rating Scales, Severity of Illness Index, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, Rats, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Augmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive Disorder

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks